Acquisition Opportunity Castle Biosciences' acquisition of Cernostics creates an immediate channel for TissueCypher, enabling faster market access through Castle's established customer base and field teams.

Platform Synergy TissueCypher's tissue systems biology approach delivers richer, quantitative insights from whole slide multiplexed imaging, offering a compelling complement to Castle's existing diagnostic portfolio.

BE Market Expansion Evidence from the BE collaboration with TissueCypher Barrett points to a strong opportunity to expand into Barrett's Esophagus risk stratification workflows within GI clinics and surveillance programs.

Target Customers Key sales targets include pathology labs, cancer centers, and academic medical centers seeking objective, data driven tissue analytics to improve diagnostic accuracy and prognostic confidence.

Growth Potential With funding backing and an active research platform, Cernostics can scale more rapidly within a larger corporate ecosystem, leveraging Castle's resources to accelerate product adoption.